Patents by Inventor Daniel A. PRYMA

Daniel A. PRYMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiolabeled and fluorescent PARP inhibitors for imaging and radiotherapy
    Patent number: 11161865
    Abstract: The present disclosure relates to compounds of Formula I and II, wherein R1-R20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 2, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert H. Mach, Sean Reilly, Mehran Makvandi, Kuiying Xu, Daniel A. Pryma, Roger A. Greenberg
  • RADIOLABELED AND FLUORESCENT PARP INHIBITORS FOR IMAGING AND RADIOTHERAPY
    Publication number: 20200109156
    Abstract: The present disclosure relates to compounds of Formula I and II, wherein R1-R20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject.
    Type: Application
    Filed: May 24, 2018
    Publication date: April 9, 2020
    Inventors: Robert H. MACH, Sean REILLY, Mehran MAKVANDI, Kuiying XU, Daniel A. PRYMA, Roger A. GREENBERG
  • -astatine containing radiotherapeutics for the treatment of cancer
    Patent number: 10457642
    Abstract: Described herein is an alpha-emitting radionuclide, 211At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R1-R4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-(211At)—N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: October 29, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel A. Pryma, Brian P. Lieberman, Mehran Makvandi, Robert H. Mach
  • 211-ASTATINE CONTAINING RADIOTHERAPEUTICS FOR THE TREATMENT OF CANCER
    Publication number: 20180162818
    Abstract: Described herein is an alpha-emitting radionuclide, 211At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R1-R4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-(211At)—N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.
    Type: Application
    Filed: April 26, 2016
    Publication date: June 14, 2018
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: Daniel A. PRYMA, Brian p. LIEBERMAN, Mehran MAKVANDI, Robert H. MACH